Dissecting Brain Network Ageing Using Whole Brain Imaging
Funder
National Health and Medical Research Council
Funding Amount
$692,964.00
Summary
In this proposal, we will make the first attempt to map the whole brain activity change during ageing using a series of state-of-the-art techniques. We will also identify genetic and pharmacological interventions that improve brain network function during ageing. Outcomes from this research will provide an unprecedented understanding of functional ageing within the brain and identify therapeutic interventions to prevent this process.
Are Oligodendrocytes The Missing Link In Amyotrophic Lateral Sclerosis Pathogenesis?
Funder
National Health and Medical Research Council
Funding Amount
$1,054,405.00
Summary
Amyotrophic Lateral Sclerosis (ALS) is a debilitating and progressive neurodegenerative disease. Recent research suggests important cells of the central nervous system called glia play a role in disease onset and progression. We are interested in a type of glia called oligodendrocytes; they are crucial for supporting the survival of the cells that die in ALS. Only through understanding the underlying biology of ALS can we aim to identify effective therapies that will benefit patients.
Serum Neurofilament Light As A Biomarker To Improve Management Of Mild Traumatic Brain Injuries
Funder
National Health and Medical Research Council
Funding Amount
$1,092,781.00
Summary
There is increasing awareness that mild traumatic brain injuries (mTBIs), such as concussions, can lead to persistent or permanent neurological symptoms. Nonetheless, the identification and management of mTBIs remains notoriously difficult. In this proposal, we will assess exactly how a novel blood test can be implemented to assist in mTBI diagnosis, and the identification and management of individuals at risk of suffering persistent or chronic neurological problems.
Betacellulin: Defining A Novel Sub-type In Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$907,515.00
Summary
Schizophrenia is a severe lifelong mental disorder affecting 0.7% of the world population with only partially effective symptomatic treatments. Its cause is unknown and thus cures cannot be developed currently. A promising candidate is betacellulin a growth factor which is very reduced in the brain and blood of people with schizophrenia. Little is known about its role in the brain and this project seeks to identify its relevance to schizophrenia as a step to develop new treatments.
Imaging, Fluid And Genetic Markers Of Alzheimer's Disease
Funder
National Health and Medical Research Council
Funding Amount
$1,519,004.00
Summary
Markers of pathology and inflammation are useful tools for the diagnosis and staging of neurodegenerative conditions such as Alzheimer's disease. This approach will deepen our basic understanding of this disease, improving early detection and prediction of cognitive impairment. This work will make possible more accurate diagnosis, and improved monitoring of therapeutic interventions.
Uncovering The Neural Mechanisms Of Obsessive-compulsive Disorder Using Brain Modelling
Funder
National Health and Medical Research Council
Funding Amount
$581,628.00
Summary
Obsessive-compulsive disorder (OCD) is an incurable mental illness and current therapies only mitigate its symptoms for a portion of individuals. Thus, there is a need to identify the neural causes of OCD to develop personalised therapies. We will combine mathematical modelling, computer simulations, and clinical and neuroimaging data to develop the first model of OCD. Outcomes from this study will enable targeted OCD research and the discovery of brain mechanisms supporting treatment response.
Simulating And Stimulating The Blood-Brain-Barrier: A Platform For Investigating Non-pharmaceutical Alzheimer's Therapy
Funder
National Health and Medical Research Council
Funding Amount
$680,758.00
Summary
Alzheimer's disease is a looming public health threat worldwide. Despite the widespread acknowledgement of this issue, there are a lack of effective drugs that can slow disease progression. This project aims to investigate a new class of non-pharmaceutical treatment methods based on controlled acoustic, electrical and optical stimulation methods to treat and reverse the base causes of Alzheimer's disease.
The blood-brain barrier is a major impediment to the treatment of brain tumours because it prevents most anti-cancer drugs from entering the brain, and brain tumour, from the bloodstream. This proposal examines new approaches to open the blood-brain barrier to allow the use of existing highly potent anti-cancer drugs as brain cancer therapies. Successful outcomes of this work could lead to substantial improvements in the outcomes for brain tumour patients.
The Interactive Effects Of Dietary Saturated Fat And Apolipoprotein-E Genotype On Peripheral Metabolism Of Lipoprotein-amyloid And Neurovascular Integrity.
Funder
National Health and Medical Research Council
Funding Amount
$637,536.00
Summary
This project is based on a remarkable discovery which suggests that in some individuals, Alzheimer's disease may be a consequence of corruption of microscopic blood vessels that supply brain, damaged as a consequence of exaggerated exposure in blood to a protein produced principally in liver. The project will explore this pathway further in subjects at heightened risk of Alzheimer's disease and in humanised animal models. The findings may provide new opportunities for prevention and treatment.
Glia And The Progression Of Parkinson's Disease: Bystanders Or Villains?
Funder
National Health and Medical Research Council
Funding Amount
$534,838.00
Summary
Parkinson's disease (PD) is a chronic and progressive neurodegenerative disease with no cures or effective treatments. We know where in the brain PD begins but how it spreads to affect more and more cells is unknown. This lack of understanding has been a barrier to treatment development. In this project we will use new models that will enable unprecedented insight into this process of disease spreading, and in doing so will reveal new targets for therapeutic development.